Innoviva (INVA) Income from Continuing Operations (2010 - 2026)
Innoviva's (INVA) quarterly Income from Continuing Operations came in at 186595000.0 in Q1 2026, up 500.51% YoY from 31072599.77 in Q1 2025, and up 1191.71% on a QoQ basis from 17092000.0 in Q4 2025.
Powered by 
Analysis
Innoviva (INVA) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 17 years of Income from Continuing Operations data on file, last reported at 186595000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 500.51% year-over-year to 186595000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 340217000.0 (up 223.11% YoY) and the FY2025 annual result came in at 326862000.0, up 1329.41% from the prior year.
- Income from Continuing Operations advanced to 186595000.0 in Q1 2026, from 17092000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 288576000.0 in Q3 2022 to a low of 198174000.0 in Q4 2024.
- A 5-year average of 33910058.82 and a median of 21395000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations slumped 2757.85% — and 2025, when it soared 3359.15%.
- Tracing INVA's Income from Continuing Operations over 5 years: stood at 15903000.0 in 2022, then jumped by 36.0% to 10178000.0 in 2023, then tumbled by 1847.08% to 198174000.0 in 2024, then surged by 91.38% to 17092000.0 in 2025, then jumped by 1191.71% to 186595000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 186595000.0 (Q1 2026), 17092000.0 (Q4 2025), and 107026000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Innoviva | 1.56 Bn | 984.81 Mn | 90.62 Mn | -83.42 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -83.42 Mn |
| Mar 31, 2026 | 186.56 Mn |
| Dec 31, 2025 | -13.82 Mn |
| Sep 30, 2025 | 107.01 Mn |
| Jun 30, 2025 | 63.69 Mn |
| Mar 31, 2025 | -46.59 Mn |
| Dec 31, 2024 | -10.54 Mn |
| Sep 30, 2024 | 3.06 Mn |
| Jun 30, 2024 | -34.68 Mn |
| Mar 31, 2024 | 36.52 Mn |
| Dec 31, 2023 | -6.58 Mn |
| Sep 30, 2023 | 118.19 Mn |
| Jun 30, 2023 | 1.28 Mn |
| Mar 31, 2023 | 34.84 Mn |
| Dec 31, 2022 | -10.33 Mn |
| Sep 30, 2022 | 288.54 Mn |
| Jun 30, 2022 | 21.40 Mn |
| Mar 31, 2022 | 37.82 Mn |
| Dec 31, 2021 | -6.05 Mn |
| Sep 30, 2021 | 323.19 Mn |